INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$1.30MFY2025, -32.1% a year since FY2019